February 2026
Anxiety
What February 2026's 21 new studies found, synthesized from the papers below. All Anxiety research →
The synthesis
Synthesized from 14 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Anxiety, generalized anxiety disorder, GAD, panic disorder, anxiety disorder, then ranked by relevance.
In February 2026, research on anxiety showed that psilocybin, ketamine, and mindfulness-based interventions consistently reduced anxiety symptoms across diverse populations, including those with post-treatment Lyme disease, PTSD, and endometriosis. Effect sizes ranged from moderate to large, but many studies were open-label, uncontrolled, or had small samples, limiting causal inference. The evidence is strongest for psilocybin-assisted therapy and mindfulness, though durability beyond 6 months and comparisons to active controls remain understudied.
Confidence in the evidence
Moderate- Multiple studies (RCTs, open-label, retrospective) consistently show anxiety reduction across different interventions and populations.
- Several studies had small samples (n=10-56) or lacked control groups, increasing risk of bias.
- One large meta-analysis of SG-MBIs (37 studies, n=3199) provides robust evidence for mindfulness-based interventions.
- Real-world data from a compassionate-use cohort (n=115) and a large retrospective analysis (n=374) support effectiveness in clinical settings.
How we rate confidence
Confidence reflects the strength of the underlying evidence, not whether the result is favorable. It weighs the number and size of studies, their design (randomized trials count for more than observational or single-case work), how consistently they point the same way, and their risk of bias.
Tiers run from Insufficient to High. High is rare in this field: small, early, or open-label studies land lower even when their direction is encouraging.
Evidence by study
Direction is each study's finding relative to your question: Supports, Opposes, No effect, Mixed, or Unclear.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Pilot study of psilocybin in patients with post-treatment lyme disease 2026 | open-label pilot study | 20 | Supports | Psilocybin significantly reduced PTLD symptom burden and improved quality of life, with benefits sustained through 6 months. |
| Baseline Mood and “Relational Triad” Predict Acute Qualities of Psychedelic Experience 2026 | observational longitudinal | 654 | Supports | Baseline anxiety predicted more challenging psychedelic experiences, while mindfulness and social connectedness predicted fewer challenging experiences. |
| Sense-Making Around Psilocybin in UK Women Experiencing Cancer-Related Existential Distress: An Interpretative Phenomenological Analysis 2026 | qualitative | 7 | Supports | Participants viewed psilocybin as a needed alternative for cancer-related anxiety and depression, citing barriers like illegality. |
| Dance Movement Therapy Osho Kundalini Sebagai Media Untuk Menurunkan Gejala Kecemasan, Stres, dan Depresi Pada Penyandang Disabilitas Mental 2026 | pre-experimental one-group pretest-posttest | 15 | Supports | Dance Movement Therapy with Osho Kundalini music significantly reduced anxiety, stress, and depression scores. |
| At-Home Ketamine-Assisted Therapy for Post-Traumatic Stress Disorder: A Real-World Retrospective Analysis 2026 | retrospective analysis | 374 | Supports | Anxiety (GAD-7) significantly decreased alongside PTSD symptoms after 6 sessions of at-home ketamine therapy. |
| Effect of mindful breathing on anxiety, depression, and quality of life among women with endometriosis. 2026 | quasi-experimental | 108 | Supports | Mindful breathing exercises significantly reduced anxiety scores compared to baseline and control group. |
| App-based self-guided mindfulness training for adults with epilepsy: a six-week single-arm feasibility study. 2026 | single-arm feasibility study | 10 | Supports | App-based mindfulness training showed preliminary anxiety reduction (GAD-7 median difference -5.50) and improved quality of life. |
| MDMA and psilocybin regulate oligodendrocyte-lineage cell numbers and anxiety-like behaviors in a rat model of fear. 2026 | animal study | 210 | Supports | Psilocybin and MDMA reduced anxiety-like behaviors in a fear-conditioned rat model, with effects linked to myelin plasticity. |
| Real-world effectiveness and safety of psychedelic-assisted psychotherapy: Outcomes from a large-scale compassionate use cohort in Switzerland. 2026 | retrospective compassionate-use cohort | 115 | Supports | LSD or psilocybin-assisted therapy significantly reduced trait anxiety (STAI-T) from pre- to post-treatment. |
| The effectiveness of second-generation mindfulness interventions on anxiety and depression: A systematic review and meta-analysis. 2026 | systematic review and meta-analysis | 3199 | Supports | Second-generation mindfulness interventions significantly reduced anxiety symptoms (g = 0.61) compared to controls. |
| Hope for Neurotic Disorders: A Summary of New Zealand Research on the Development of Biomarkers and Novel Treatments. 2026 | review/summary | Supports | Ketamine, LSD, and psilocybin show promise as novel treatments for anxiety disorders, with EEG biomarker developments. | |
| Spirituality and Medicine in the USA, Europe, and the UK: A Systematic Review and Meta-analysis of Integrative Approaches to Patient Satisfaction, Quality of Life, and Health Outcomes. 2026 | systematic review and meta-analysis | Supports | Spiritual interventions (meditation, prayer, mindfulness) significantly improved anxiety symptoms (effect size 0.70). | |
| A retrospective report of a ketamine-augmented, transdiagnostic psychiatric outpatient psychotherapy program 2026 | retrospective chart review | 56 | Supports | Ketamine-augmented transdiagnostic program significantly reduced anxiety (GAD-7) and improved quality of life. |
| Involvement of Adenosine A2A Receptors in Anxiety-Like Behaviors in Tetrahydrocannabinol-Treated Mice. 2026 | animal study | Opposes | THC induced anxiety-like behavior in mice, mediated by adenosine A2A receptor interactions. |
Psilocybin significantly reduced PTLD symptom burden and improved quality of life, with benefits sustained through 6 months.
open-label pilot study Sample size: 20
Baseline anxiety predicted more challenging psychedelic experiences, while mindfulness and social connectedness predicted fewer challenging experiences.
observational longitudinal Sample size: 654
Participants viewed psilocybin as a needed alternative for cancer-related anxiety and depression, citing barriers like illegality.
qualitative Sample size: 7
Dance Movement Therapy with Osho Kundalini music significantly reduced anxiety, stress, and depression scores.
pre-experimental one-group pretest-posttest Sample size: 15
Anxiety (GAD-7) significantly decreased alongside PTSD symptoms after 6 sessions of at-home ketamine therapy.
retrospective analysis Sample size: 374
Mindful breathing exercises significantly reduced anxiety scores compared to baseline and control group.
quasi-experimental Sample size: 108
App-based mindfulness training showed preliminary anxiety reduction (GAD-7 median difference -5.50) and improved quality of life.
single-arm feasibility study Sample size: 10
Psilocybin and MDMA reduced anxiety-like behaviors in a fear-conditioned rat model, with effects linked to myelin plasticity.
animal study Sample size: 210
LSD or psilocybin-assisted therapy significantly reduced trait anxiety (STAI-T) from pre- to post-treatment.
retrospective compassionate-use cohort Sample size: 115
Second-generation mindfulness interventions significantly reduced anxiety symptoms (g = 0.61) compared to controls.
systematic review and meta-analysis Sample size: 3199
Ketamine, LSD, and psilocybin show promise as novel treatments for anxiety disorders, with EEG biomarker developments.
review/summary
Spiritual interventions (meditation, prayer, mindfulness) significantly improved anxiety symptoms (effect size 0.70).
systematic review and meta-analysis
Ketamine-augmented transdiagnostic program significantly reduced anxiety (GAD-7) and improved quality of life.
retrospective chart review Sample size: 56
THC induced anxiety-like behavior in mice, mediated by adenosine A2A receptor interactions.
animal study
Points of agreement
- Psilocybin and ketamine consistently reduce anxiety symptoms across multiple clinical populations (PTLD, PTSD, cancer-related distress, treatment-resistant disorders).
- Mindfulness-based interventions (including app-based and second-generation MBIs) reliably decrease anxiety in diverse groups (endometriosis, epilepsy, general adults).
- Real-world and compassionate-use data support the effectiveness of psychedelic-assisted therapy for anxiety in routine clinical settings.
Conflicts
- One animal study found that THC induced anxiety-like behavior, contrasting with the anxiolytic effects of other compounds like psilocybin and ketamine.
- The role of acute psychedelic experience quality (mystical vs. challenging) in predicting anxiety outcomes is not fully consistent across studies.
Gaps
- Durability of anxiety reduction beyond 6 months is rarely reported.
- Most psychedelic studies lack active placebo or comparator groups, limiting causal inference.
- Few studies examine anxiety in underrepresented populations (e.g., non-Western, elderly, children).
- Optimal dosing, session frequency, and long-term safety of repeated psychedelic use for anxiety remain unstudied.
- Mechanistic studies in humans (e.g., neuroimaging, biomarkers) are sparse.